A5075486570- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Urologic and reproductive health conditions
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Urinary Tract Infections Management
- Acute Myeloid Leukemia Research
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Sexual function and dysfunction studies
- Multiple Myeloma Research and Treatments
- Urinary Bladder and Prostate Research
- Male Reproductive Health Studies
- Hormonal and reproductive studies
- Colorectal Cancer Surgical Treatments
- Cancer Diagnosis and Treatment
NYU Langone Health
2022-2025
New York University
2022-2025
The University of Queensland
2025
Zhongnan Hospital of Wuhan University
2024
Wuhan University
2024
Duke Medical Center
2019-2023
Duke University
2021-2023
BeiGene (China)
2020-2023
Columbia University Irving Medical Center
2023
Dalian Medical University
2022
Abstract Poly-(ADP-ribose) polymerase inhibitors (PARPi) selectively kill breast and ovarian cancers with defects in homologous recombination (HR) caused by BRCA1/2 mutations. There is also clinical evidence for the utility of PARPi without BRCA mutations, but underlying mechanism not clear. Here, we report that deubiquitylating enzyme USP15 affects cancer cell response to regulating HR. Mechanistically, recruited DNA double-strand breaks (DSBs) MDC1, which requires FHA domain MDC1...
Abstract Purpose: The primary objective was to evaluate safety of 3-(1′-hexyloxyethyl)pyropheophorbide-a (HPPH) photodynamic therapy (HPPH-PDT) for dysplasia and early squamous cell carcinoma the head neck (HNSCC). Secondary objectives were assessment treatment response reporters an effective PDT reaction. Experimental Design: Patients with histologically proven oral dysplasia, in situ, or early-stage HNSCC enrolled two sequentially conducted dose escalation studies expanded cohort at...
Background: Early invasive carcinoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The natural history these early lesions is unknown. Methods: Pancreatic surgical databases from 4 high-volume centers were queried for IPMNs, components measuring 20 mm or less. All cases reviewed by GI gastrointestinal pathologists, and pathologic features analyzed to identify predictors recurrence survival. Results: A total 70 small IPMN-associated...
Cancer incidence and mortality varies across region, sex country's economic status. While most studies focused on global trends, this study aimed to describe analyse cancer in Asia, focusing site, sex, region income Age-standardised rates of were extracted from the GLOBOCAN 2012 database. ratios (MIRs) calculated represent survival. The data analysed based four regions Asia income. rate is lower compared West but for MIR, it reverse. In common cancers men are lung, stomach, liver, colorectal...
Background Ociperlimab, a novel, humanized monoclonal antibody (mAb), binds to T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) high affinity specificity. Tislelizumab is an anti-programmed cell death protein 1 mAb. We report results from phase I, first-in-human, dose escalation study evaluating the safety, pharmacokinetics (PK), preliminary antitumor activity of ociperlimab plus tislelizumab in patients advanced solid tumors. Methods Eligible...
BACKGROUND Several studies have suggested that low 25(OH) vitamin D 3 levels may be prognostic in some malignancies, but no evaluated their impact on treatment outcome patients with acute myeloid leukemia (AML). METHODS Vitamin were 97 consecutive, newly diagnosed, intensively treated AML. MicroRNA expression profiles and single nucleotide polymorphisms (SNPs) the pathway genes correlated outcome. RESULTS Thirty‐four (35%) had normal (32‐100 ng/mL), 34 insufficient (20‐31.9 29 (30%)...
Abstract Background The purpose of this study was for us to report results regarding the safety 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses. Methods A single‐institution, phase Ib, open label, noncomparative HPPH‐PDT patients with high‐risk dysplasia, carcinoma situ, T1 squamous cell (SCC) larynx. primary outcomes were maximum tolerated dose (MTD), secondary outcome...
This phase 2 study explored tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy as first-line treatment of advanced lung cancer.Eligible patients had histologically/cytologically confirmed advanced/metastatic nonsquamous non-small cell cancer (NSQ), squamous NSCLC (SQ), or extensive-stage small (SCLC). All received tislelizumab 200 mg 4-6 cycles platinum-doublet. The NSQ cohort pemetrexed + platinum Q3W for 4 followed by maintenance, the SQ paclitaxel (A)...
Pancreatic ductal adenocarcinoma (PDAC) is a highly immune-suppressive tumor with low response rate to single checkpoint blockade therapy. ETS homologous factor (EHF) suppressor in PDAC. Here, we report novel function of EHF pancreatic cancer immune microenvironment editing and efficacy prediction for anti-PD1 Our findings support that the deficiency tumoral induced accumulation regulatory T (T reg) cells myeloid-derived (MDSCs) decrease number tumor-infiltrating CD8+ cells. Mechanistically,...
To evaluate the lymph node yield (LNY) during robot-assisted radical cystectomy (RC), as it has been questioned to whether robot assistance allows adequate pelvic LN dissection (LND), especially initial experience.In all, 67 consecutive patients were selected for RC and LND with open urinary diversion from October 2005 November 2007. Data was collected prospectively in a standard fashion part of quality assurance programme. Nine excluded (three had unresectable disease six underwent...
Background and Objectives Photodynamic therapy (PDT) with porfimer sodium, FDA approved to treat premalignant lesions in Barrett's esophagus, causes photosensitivity for 6–8 weeks. HPPH (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a) shows minimal photosensitization of short duration promising efficacy preclinical studies. Here we explore toxicity optimal drug light dose endoscopic HPPH-PDT. We also want know the one time treatment Study Design/Materials Methods Two nonrandomized...